Key result
The tacrolimus-eluting Janus stent was associated with a 22% rate of major adverse coronary events at 6 months in unselected patients undergoing percutaneous coronary intervention.
Observational (n=118)
Yes
The tacrolimus-eluting Janus stent demonstrated higher than expected rates of MACE, TLR, and stent thrombosis in an unselected, high-risk PCI population.
No takes yet. Share an insight, caveat, or question.
High MACE rates with the Janus stent in unselected PCI warrant clinical caution; leaves open safety questions pending randomized data.
Romagnoli et al. (2008) conducted an observational in Coronary artery disease requiring percutaneous coronary intervention (n=118). Tacrolimus-eluting Carbofilm-coated Janus stent was evaluated on Major adverse coronary events (MACE) defined as the composite of cardiovascular death, nonfatal myocardial infarction (MI) and target lesion revascularization (TLR). The tacrolimus-eluting Janus stent was associated with a 22% rate of major adverse coronary events at 6 months in unselected patients undergoing percutaneous coronary intervention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: